Premium
Intensive rituximab regimen in immune‐mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment
Author(s) -
Barba Christophe,
Peyre Marion,
Galicier Lionel,
Cathebras Pascal,
Ranta Dana,
Malot Sandrine,
Veyradier Agnès,
Coppo Paul
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17170
Subject(s) - rituximab , medicine , thrombotic thrombocytopenic purpura , adamts13 , regimen , cd20 , asymptomatic , immunology , gastroenterology , antibody , platelet
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom